Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buntanetap
- Development stage
- Phase 3
- Lead developer
- Annovis Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Buntanetap (formerly known as Posiphen or ANVS-401) is an orally bioavailable small molecule being developed by Annovis Bio for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's disease. It acts as a translational inhibitor that targets the mRNA of several neurotoxic proteins by binding to the iron-responsive element (IRE) in their 5' untranslated region (UTR). This mechanism specifically blocks the translation of amyloid precursor protein (APP), tau, alpha-synuclein, and TDP-43. By reducing the levels of these neurotoxic proteins, buntanetap aims to restore axonal transport, reduce neuroinflammation, and improve synaptic transmission. The drug is currently being evaluated in Phase 3 clinical trials for early Alzheimer's disease, focusing on both symptomatic improvement and disease-modifying potential.
- Brand names
- Buntanetap
- Other names
- Posiphenbuntanetap tartrate
02
Targets
TARDBP (TAR DNA-binding protein 43)Iron-responsive element in the 5'-untranslated region of Amyloid Precursor Protein mRNAIron-responsive element in the 5'-untranslated region of neurotoxic protein mRNAsIron-responsive element in the 5'-untranslated region of microtubule-associated protein tau mRNAAlpha-synuclein mRNA 5'-untranslated region iron-responsive element
Beyond the preview
Go deeper on buntanetap.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buntanetap.